Empagliflozin prevents doxorubicin-induced myocardial dysfunction

BACKGROUND: Empagliflozin showed efficacy in controlling glycaemia, leading to reductions in HbA1c levels, weight loss and blood pressure, compared to standard treatment. Moreover, the EMPA-REG OUTCOME trial demonstrated a 14% reduction of major adverse cardiovascular events (MACE), a 38% reduction...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cardiovasc Diabetol
Autors principals: Sabatino, Jolanda, De Rosa, Salvatore, Tammè, Laura, Iaconetti, Claudio, Sorrentino, Sabato, Polimeni, Alberto, Mignogna, Chiara, Amorosi, Andrea, Spaccarotella, Carmen, Yasuda, Masakazu, Indolfi, Ciro
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7229599/
https://ncbi.nlm.nih.gov/pubmed/32414364
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-020-01040-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars